| Metric | Value (₹ Cr) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 181.68 | 7.5% | 5.5% |
| Total Income | 186.22 | 6.9% | 6.9% |
| Expenditure | 147.99 | 6.7% | 12.3% |
| PBT | 49.45 | 39.6% | 227.7% |
| Net Profit | 36.85 | 40.2% | 777.4% |
| OPM | 27.66% | 6.66pp | 23.21pp |
| NPM | 19.79% | 4.69pp | 17.38pp |
| EPS | 22.28 | 40.1% | 777.2% |
RPG Life Sciences Q2 FY26: Revenue up by 7.6% Q-o-Q, EBITDA margin at 24.0%
17 Oct 2025 · 17 Oct 2025, 08:42 pm
Summary
RPG Life Sciences Limited has announced its financial results for the second quarter and half year ended September 30, 2025. The company recorded a 7.6% Q-o-Q and 5.5% Y-o-Y increase in revenue. EBITDA margins stood at a strong 24%, reflecting operational efficiency. The domestic formulations business is delivering market-beating performance with a growth of 13.5% in H1 FY26 versus Indian Pharma Market which recorded a growth of 7.4% in H1.
Key Highlights
- 1
Q-o-Q Revenue from operations Q2 FY26: Rs. 181.7 crores vs. Rs. 168.9 crores
- 2
Y-o-Y Revenue from operations Q2 FY26: Rs. 181.7 crores vs. Rs. 172.2 crores
- 3
H1 FY26 Highlights: Rs. 350.6 crores vs. Rs. 337.6 crores
- 4
Domestic formulations business growth in H1 FY26: 13.5%
- 5
Indian Pharma Market growth in H1 FY26: 7.4%
Management Comments
Mr. Ashok Nair
In Q2, we have further strengthened our growth trajectory, driven by disciplined execution and a clear strategic focus. Our transformation agenda is anchored in a legacy of quality and focused on enhancing patient outcomes. We are making steady progress in our International Formulations and API business, supported by new customer acquisitions, expansion into both emerging and regulated markets, and launch of molecules that enhance our therapeutic footprint.”
Informational and educational content only. Not investment advice.